Literature DB >> 14715839

Melatonin in patients with reduced REM sleep duration: two randomized controlled trials.

Dieter Kunz1, Richard Mahlberg, Cordula Müller, Amely Tilmann, Frederik Bes.   

Abstract

Recent data suggest that melatonin may influence human physiology, including the sleep-wake cycle, in a time-dependent manner via the body's internal clock. Rapid-eye-movement (REM) sleep expression is strongly circadian modulated, and the impact of REM sleep on primary brain functions, metabolic processes, and immune system function has become increasingly clear over the past decade. In our study, we evaluated the effects of exogenous melatonin on disturbed REM sleep in humans. Fourteen consecutive outpatients (five women, nine men; mean age, 50 yr) with unselected neuropsychiatric sleep disorders and reduced REM sleep duration (25% or more below age norm according to diagnostic polysomnography) were included in two consecutive, randomized, double-blind, placebo-controlled, parallel design clinical trials. Patients received 3 mg melatonin daily, administered between 2200 and 2300 h for 4 wk. The results of the study show that melatonin was significantly more effective than placebo: patients on melatonin experienced significant increases in REM sleep percentage (baseline/melatonin, 14.7/17.8 vs. baseline/placebo, 14.3/12.0) and improvements in subjective measures of daytime dysfunction as well as clinical global impression score. Melatonin did not shift circadian phase or suppress temperature but did increase REM sleep continuity and promote decline in rectal temperature during sleep. These results were confirmed in patients who received melatonin in the second study (REM sleep percentage baseline/placebo/melatonin, 14.3/12.0/17.9). In patients who received melatonin in the first study and placebo in the second, the above mentioned effects outlasted the period of melatonin administration and diminished only slowly over time (REM sleep percentage baseline/melatonin/placebo, 14.7/17.8/16.2). Our findings show that exogenous melatonin, when administered at the appropriate time, seems to normalize circadian variation in human physiology. It may, therefore, have a strong impact on general health, especially in the elderly and in shift workers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715839     DOI: 10.1210/jc.2002-021057

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Evaluation of the association between sleep apnea and polyunsaturated fatty acids profiles in patients after percutaneous coronary intervention.

Authors:  Keisuke Nakabayashi; Kentaro Jujo; Katsumi Saito; Toshiaki Oka; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2017-06-19       Impact factor: 2.037

2.  Sleep disorders and inflammatory disease activity: chicken or the egg?

Authors:  Parth J Parekh; Edward C Oldfield Iv; Vaishnavi Challapallisri; J Catsby Ware; David A Johnson
Journal:  Am J Gastroenterol       Date:  2014-08-26       Impact factor: 10.864

3.  ipRGCs: possible causation accounts for the higher prevalence of sleep disorders in glaucoma patients.

Authors:  Zhen-Zhen Guo; Shan-Ming Jiang; Li-Ping Zeng; Li Tang; Ni Li; Zhu-Ping Xu; Xin Wei
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

Review 4.  Melatonin therapy for REM sleep behavior disorder: a critical review of evidence.

Authors:  Ian R McGrane; Jonathan G Leung; Erik K St Louis; Bradley F Boeve
Journal:  Sleep Med       Date:  2014-10-13       Impact factor: 3.492

5.  Ramelteon for Insomnia Related to Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Rachel E Fargason; Karen Gamble; Kristin T Avis; Rachel C Besing; Cherry W Jackson; Marshall E Cates; Roberta May
Journal:  Psychopharmacol Bull       Date:  2011-05-15

6.  Biological Consequences of Disturbed Sleep: Important Mediators of Health?

Authors:  Michele L Okun
Journal:  Jpn Psychol Res       Date:  2011-05-01

Review 7.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 8.  Treatment of REM Sleep Behavior Disorder.

Authors:  Youngsin Jung; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

9.  Melatonin and tryptophan affect the activity-rest rhythm, core and peripheral temperatures, and interleukin levels in the ringdove: changes with age.

Authors:  Sergio D Paredes; Ana María Marchena; Ignacio Bejarano; Javier Espino; Carmen Barriga; Rubén V Rial; Russel J Reiter; Ana B Rodríguez
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-10       Impact factor: 6.053

10.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.